It is a pharma private limited company based in New Delhi, Delhi, India, established in 2016.
2016 | New Delhi, Delhi, India | ActiveSupernova Pharmaceuticals Private Limited, a active private limited company, was established on 18 August 2016 in New Delhi, Delhi, India. Engaging in pharmaceutical retailers & distributors within the trade sector, it holds CIN: U74999DL2016PTC304616. Registered under ROC Roc Delhi. it is unlisted. It has an authorized capital of ₹1.00 M and a paid-up capital of ₹0.50 M.
It upholds a compliant status. Its leadership includes Om Prakash Tanwar (Director), Rukmani (Director), Mohan Singh Rawat (Director). Past directors included Nitin Kumar, Ruchika Sodhi, Anupma Chandel. Its latest AGM occurred on 30 September 2019, with the balance sheet filed on 31 March 2019. It is based at B-11, Somdutt, Chamber –Ii, Bhikaji Cama Place New Delhi -110066, New Delhi, Delhi, 110066.
U74999DL2016PTC304616
304616
18 August 2016
₹1.00 M
₹0.50 M
Roc Delhi
Unlisted
Active
Explore comprehensive insights into Supernova Pharmaceuticals Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Om Prakash Tanwar | Director | 17 Feb 2021 | Current |
| Rukmani | Director | 24 Nov 2018 | Current |
| Mohan Singh Rawat | Director | 24 Nov 2018 | Current |
| Rahul Malik | Director | 17 Feb 2021 | Current |
| Devi Dayal | Director | 24 Nov 2018 | Current |
| Amardeep Kaur | Director | 17 Feb 2021 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 26 Nov 2018 | Past |
| Pramod Abcsdd | Director | 17 Feb 2021 | Past |
| Pramod Abcsdd | Director | 26 Nov 2018 | Past |
| Pramod Abcsdd | Director | 26 Nov 2018 | Past |
| Pramod Abcsdd | Director | 17 Feb 2021 | Past |
| Pramod Abcsdd | Director | 26 Nov 2018 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Supernova Pharmaceuticals Private Limited, for the financial year ended 2019, experienced significant growth in revenue, with a 120.24% increase. The company also saw a substantial fall in profitability, with a 2925.68% decrease in profit. The company's net worth observed a substantial decline by a decrease of 14.78%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2019, Supernova Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Unlock and access historical data on people associated with Supernova Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Supernova Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Supernova Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Om Prakash Tanwar was appointed as a Director was appointed as a Director on 17 Feb 2021 & has been associated with this company since 4 years 9 months . was recorded as a recent event.
The activity Rahul Malik was appointed as a Director was appointed as a Director on 17 Feb 2021 & has been associated with this company since 4 years 9 months . was completed.
Amardeep Kaur was appointed as a Director was appointed as a Director on 17 Feb 2021 & has been associated with this company since 4 years 9 months . was recorded as a recent event.
Progress on Supernova Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2019 as per latest MCA records. was documented.
The activity Supernova Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2019 with Roc Delhi. was completed.
The activity Rukmani was appointed as a Director was appointed as a Director on 24 Nov 2018 & has been associated with this company since 7 years 8 days . was completed.
The CIN of Supernova Pharmaceuticals Private Limited is U74999DL2016PTC304616.
Supernova Pharmaceuticals Private Limited is headquartered at B-11, Somdutt, Chamber –Ii, Bhikaji Cama Place New Delhi -110066, New Delhi, Delhi, 110066.
Supernova Pharmaceuticals Private Limited was incorporated on 18 August 2016.
The current directors of Supernova Pharmaceuticals Private Limited are
The primary industry of Supernova Pharmaceuticals Private Limited is Trade.
Supernova Pharmaceuticals Private Limited is unlisted.
The authorized capital of Supernova Pharmaceuticals Private Limited is ₹1.00 M, and the paid-up capital is ₹0.50 M.
The compliance status of Supernova Pharmaceuticals Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX